01273nas a2200349   4500000000100000008004100001260001600042653001500058653001700073100001400090700001500104700001600119700001600135700001200151700001200163700001300175700001300188700001500201700001300216700001300229700001700242700001500259700001200274700001600286700001200302700001500314700001400329245014000343856007300483520035300556022001400909       2014                            d  c2014 Jan 2910aRifampicin10aBuruli ulcer1 aJansson M1 aBeissner M1 aPhillips RO1 aBadziklou K1 aPiten E1 aMaman I1 aSarfo FS1 aHuber KL1 aRhomberg A1 aSymank D1 aWagner M1 aWiedemann FX1 aNitschke J1 aKere AB1 aHerbinger K1 aAdjei O1 aLöscher T1 aBretzel G00aMolecular determination of Rifampicin resistance in clinical samples of patients with buruli ulcer disease: A comparison of two assays.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993512/pdf/zjm1246.pdf3 a<p>This study evaluates a novel assay to detect rifampicin resistance in clinical Mycobacterium ulcerans isolates. Although highly susceptible for PCR inhibitors in 50% of samples tested, the assay was 100% M. ulcerans-specific and yielded &gt;98% analyzable sequences with a lower limit of detection of 100-200 copies of the target sequence.</p>
  a1098-660X